StockpollyBeta
Get App
Popularity #4,826
LONA · NASDAQ · Biotechnology

LeonaBio (LONA)

Develops lasofoxifene for metastatic breast cancer and ATH-1105 for ALS.

$5.97
vs last close−0.08 (−1.32%)

Something off on this page? Send us feedback.

13F · 13D/G · Form 4

Insiders1.41%133.2K shares
5 holders · as of Mar 5, 2026
Strategic holders27.46%2.59M shares
2 holders · as of May 15, 2026
Other71.13%6.70M shares
remainder

9.42M company shares as of Sep 23, 2026 · holders as of their latest filing

Two share counts disagree (9.42M in the company's Sep 23, 2026 report, 3.94M elsewhere); stakes use the report.

13F · 13D/G · Form 4

HolderStakeSharesDate
Perceptive Advisors LLCStrategicdirector, 10 percent owner
19.73%1.86Mfiled Dec 23, 2025
ADAR1 Capital Management, LLCStrategic
7.72%727,481filed May 15, 2026
Mark James LittonInsiderdirector, officer: PRESIDENT and CEO
0.61%57,926filed Mar 5, 2026
Kevin ChurchInsiderofficer: CHIEF SCIENTIFIC OFFICER
0.27%25,178filed Mar 5, 2026
Mark WorthingtonInsiderofficer: GENERAL COUNSEL and CCO
0.20%18,376filed Mar 5, 2026
Martin Javier SanInsiderofficer: CHIEF MEDICAL OFFICER
0.17%15,887filed Mar 5, 2026
Robert RenningerInsiderofficer: CHIEF FINANCIAL OFFICER
0.17%15,851filed Mar 5, 2026
Oliveira Steven MichaelInsider
—5.11% of class, as filed—filed Apr 16, 2025
Sermonix Pharmaceuticals, Inc.Strategic
—36.90% of class, as filed—filed Aug 31, 2026
Joseph Edelman1Insiderdirector
3.92%369,592filed Jul 1, 2022
RTW Investments, LP2Strategic10 percent owner
2.83%266,891filed Sep 22, 2020
Leen Kawas3Insiderdirector, 10 percent owner, officer: President & CEO
0.28%26,481filed Sep 17, 2020
Glenna Mileson4Insiderofficer: Chief Financial Officer
0.17%15,993filed Dec 30, 2022
Andrew Gengos5Insiderofficer: CFO and Chief Business Officer
0.10%9,753filed Sep 5, 2024
Hans Moebius6Insiderofficer: Chief Medical Officer
0.10%9,148filed Jan 8, 2024
Kelly A. Romano7Insiderdirector
0.09%8,072filed Jun 25, 2024
Grant Pickering8Insiderdirector
0.03%2,578filed Mar 31, 2023
Rachel Lenington5Insiderofficer: COO and CDO
0.02%2,087filed Sep 5, 2024
James A. Johnson9Insiderdirector
0.01%500filed Mar 30, 2023
John M. Jr Fluke10Insiderdirector
0.00%373filed Jun 16, 2021
  1. Last filed Jul 1, 2022; leaving the company requires no filing. Not in the bar.
  2. Last filed Sep 22, 2020; leaving the company requires no filing. Not in the bar.
  3. Last filed Sep 17, 2020; leaving the company requires no filing. Not in the bar.
  4. Last filed Dec 30, 2022; leaving the company requires no filing. Not in the bar.
  5. Last filed Sep 5, 2024; leaving the company requires no filing. Not in the bar.
  6. Last filed Jan 8, 2024; leaving the company requires no filing. Not in the bar.
  7. Last filed Jun 25, 2024; leaving the company requires no filing. Not in the bar.
  8. Last filed Mar 31, 2023; leaving the company requires no filing. Not in the bar.
  9. Last filed Mar 30, 2023; leaving the company requires no filing. Not in the bar.
  10. Last filed Jun 16, 2021; leaving the company requires no filing. Not in the bar.

13F

No 13F holders on record.

13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Sermonix Pharmaceuticals, Inc.incl. Portman David J.36.90%5.50M13DAug 31, 2026
Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. +1 more19.99%1.89M13DAug 25, 2026
ADAR1 Capital Management, LLC7.70%727.5K13GMay 15, 2026
Steven Michael Oliveira5.11%13GApr 16, 2025

Form 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Mar 4, 2026
Martin Javier Sanofficer: CHIEF MEDICAL OFFICER
Sale1,720$5.3715,887
Mar 4, 2026
Kevin Churchofficer: CHIEF SCIENTIFIC OFFICER
Sale1,359$5.3725,178
Mar 4, 2026
Mark Worthingtonofficer: GENERAL COUNSEL and CCO
Sale1,328$5.3718,376
Mar 4, 2026
Robert Renningerofficer: CHIEF FINANCIAL OFFICER
Sale906$5.3715,851
Mar 4, 2026
Mark James Littondirector, officer: PRESIDENT and CEO
Sale5,156$5.3757,926
Jan 2, 2026
Mark Worthingtonofficer: General Counsel and CCO
Sale876$6.8813,978
Jan 2, 2026
Kevin Churchofficer: CHIEF SCIENTIFIC OFFICER
Sale876$6.8820,681
Jan 2, 2026
Robert Renningerofficer: Chief Financial Officer
Sale297$6.8812,857
Jan 2, 2026
Mark James Littondirector, officer: President and CEO
Sale2,586$6.8840,828
Jan 2, 2026
Martin Javier Sanofficer: CHIEF MEDICAL OFFICER
Sale1,644$6.8810,189

House and Senate disclosures

Not reported.